Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Qiagen N.V. (QGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,567,087
  • Shares Outstanding, K 225,509
  • Annual Sales, $ 1,502 M
  • Annual Income, $ 190,380 K
  • 60-Month Beta 0.92
  • Price/Sales 5.75
  • Price/Cash Flow 15.59
  • Price/Book 3.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.26
  • Number of Estimates 5
  • High Estimate 0.27
  • Low Estimate 0.25
  • Prior Year 0.26
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.86 +2.30%
on 04/22/19
41.55 -6.79%
on 04/08/19
-0.69 (-1.75%)
since 03/22/19
3-Month
35.72 +8.43%
on 02/05/19
41.55 -6.79%
on 04/08/19
+1.64 (+4.42%)
since 01/23/19
52-Week
31.93 +21.30%
on 04/25/18
41.55 -6.79%
on 04/08/19
+5.95 (+18.15%)
since 04/23/18

Most Recent Stories

More News
Detailed Research: Economic Perspectives on Brookfield Infrastructure Partners LP, QIAGEN N.V, Carbon Black, United-Guardian, Core Laboratories N.V, and Applied DNA Sciences -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Brookfield Infrastructure...

CBLK : 13.09 (+1.16%)
UG : 19.30 (-0.52%)
APDN : 0.57 (-4.67%)
BIP : 41.63 (+0.70%)
CLB : 74.56 (-0.41%)
QGEN : 38.73 (+1.95%)
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

ADXS : 3.53 (+1.44%)
QGEN : 38.73 (+1.95%)
ANIP : 69.64 (+1.21%)
XRAY : 49.76 (+0.93%)
QIAGEN N.V. to Report First Quarter 2019 Results

QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the first quarter 2019 on Monday, May 6 at approximately 22:05 Central...

QGEN : 38.73 (+1.95%)
QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the U.S. launch of its novel therascreen(R) FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) as a companion diagnostic ...

QGEN : 38.73 (+1.95%)
QIAGEN's QuantiFERON(R)-TB Passes Milestone of 60 Million Tests in Global Fight against Tuberculosis, Current Annual Run Rate Exceeds 12 Million Tests

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its modern gold standard QuantiFERON(R)-TB test for detection of latent tuberculosis (TB) infections has surpassed...

QGEN : 38.73 (+1.95%)
QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced an expansion of the content menu for the NeuMoDx(TM) 96 and 288 Molecular Systems, as well...

QGEN : 38.73 (+1.95%)
QIAGEN Highlights Profile of New QIAstat-Dx Meningitis / Encephalitis pAnel Focused on Most Prevalent Central Nervous System Pathogens

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new data of the QIAstat-Dx Meningitis / Encephalitis panel. The panel is in late stage development and being prepared...

QGEN : 38.73 (+1.95%)
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics

LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.

SYK : 186.96 (+2.64%)
AMED : 123.86 (+8.65%)
QGEN : 38.73 (+1.95%)
LH : 151.29 (+4.88%)
QIAGEN and LabCorp Launch Collaboration to Provide Day-One Access for Patients to Innovative Companion Diagnostics at the Time of Drug Approvals

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp(R) (NYSE: LH) to further accelerate the access of cancer patients to QIAGEN's...

QGEN : 38.73 (+1.95%)
LH : 151.29 (+4.88%)
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations

PLANEGG/MUNICH GERMANY / ACCESSWIRE / April 1, 2019 / Dr. Sarah Fakih joined MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) as Vice President and Head of Corporate Communications...

MOR : 24.70 (+2.96%)
QGEN : 38.73 (+1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade QGEN with:

Business Summary

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

See More

Key Turning Points

2nd Resistance Point 39.27
1st Resistance Point 39.00
Last Price 38.73
1st Support Level 38.29
2nd Support Level 37.85

See More

52-Week High 41.55
Last Price 38.73
Fibonacci 61.8% 37.88
Fibonacci 50% 36.74
Fibonacci 38.2% 35.60
52-Week Low 31.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar